BRPI1009920A2 - composições bacterianas para profilaxina e tratamento de doença degenerativa. - Google Patents

composições bacterianas para profilaxina e tratamento de doença degenerativa.

Info

Publication number
BRPI1009920A2
BRPI1009920A2 BRPI1009920A BRPI1009920A BRPI1009920A2 BR PI1009920 A2 BRPI1009920 A2 BR PI1009920A2 BR PI1009920 A BRPI1009920 A BR PI1009920A BR PI1009920 A BRPI1009920 A BR PI1009920A BR PI1009920 A2 BRPI1009920 A2 BR PI1009920A2
Authority
BR
Brazil
Prior art keywords
prophylaxine
treatment
degenerative disease
bacterial compositions
bacterial
Prior art date
Application number
BRPI1009920A
Other languages
English (en)
Inventor
Christopher Martoni
Mitchell Lawrence Jones
Satya Prakash
Original Assignee
Micropharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43031618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1009920(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Micropharma Ltd filed Critical Micropharma Ltd
Publication of BRPI1009920A2 publication Critical patent/BRPI1009920A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/10—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C2220/00—Biochemical treatment
    • A23C2220/20—Treatment with microorganisms
    • A23C2220/204—Use of bacteria which are encapsulated, entrapped or immobilised; Fermentation with these bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
BRPI1009920A 2009-05-01 2010-04-30 composições bacterianas para profilaxina e tratamento de doença degenerativa. BRPI1009920A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17474009P 2009-05-01 2009-05-01
PCT/CA2010/000660 WO2010124387A1 (en) 2009-05-01 2010-04-30 Bacterial compositions for prophylaxis and treatment of degenerative disease

Publications (1)

Publication Number Publication Date
BRPI1009920A2 true BRPI1009920A2 (pt) 2016-03-15

Family

ID=43031618

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009920A BRPI1009920A2 (pt) 2009-05-01 2010-04-30 composições bacterianas para profilaxina e tratamento de doença degenerativa.

Country Status (14)

Country Link
US (1) US10660857B2 (pt)
EP (2) EP3067056A1 (pt)
JP (2) JP6100526B2 (pt)
KR (1) KR20120015335A (pt)
CN (1) CN102481322A (pt)
AU (1) AU2010242498A1 (pt)
BR (1) BRPI1009920A2 (pt)
CA (1) CA2796929C (pt)
DK (1) DK2419114T4 (pt)
ES (1) ES2578081T5 (pt)
HR (1) HRP20160598T4 (pt)
PL (1) PL2419114T5 (pt)
RU (1) RU2571211C2 (pt)
WO (1) WO2010124387A1 (pt)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481322A (zh) * 2009-05-01 2012-05-30 微制药有限公司 预防和治疗退化性疾病的细菌组合物
CA2806619C (en) 2010-05-24 2018-05-22 Ozstar Therapeutics Pty Ltd Anti-diabetic compositions and methods
AU2011262840B2 (en) 2010-06-08 2015-02-05 Asahi Group Holdings, Ltd. Lipid metabolism-improving agent
TWI355939B (en) * 2011-01-14 2012-01-11 Genmont Biotech Inc Composition and use of probiotic strain gm-263 (ad
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
WO2013027087A1 (en) * 2011-08-23 2013-02-28 Compagnie Gervais Danone A non-reuterin-producing lactobacillus reuteri strain for treating helicobacter pylori infection
CN104024430A (zh) * 2011-08-26 2014-09-03 微生物诊断有限责任公司 用于诊断和治疗心脏缺陷的方法
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
BR112014012401A2 (pt) 2011-11-23 2017-06-13 Ozstar Therapeutics Pty Ltd composição sinérgica melhorada; método de tratamento profilático ou terapêutico de diabetes; método de melhorar a eficácia do tratamento da diabetes por sulfonilureia em um indivíduo recebendo uma terapia anti-diabética de sulfonilureia; método de tratar hiperglicemia; e método de impedir o desenvolvimento ou melhorar os efeitos colaterais ou as condições em um indivíduo tratado com uma sulfonilureia e/ou uma sulfonamida e/ou derivados e/ou metabólitos dos mesmos
WO2013081462A1 (en) * 2011-12-02 2013-06-06 Universiteit Maastricht Phytostanols for the prevention or treatment of hepatic inflammation
JP5571650B2 (ja) * 2011-12-27 2014-08-13 農業生産法人株式会社 熱帯資源植物研究所 非アルコール性脂肪性肝疾患および／または非アルコール性脂肪肝炎の治療薬
JP5525511B2 (ja) * 2011-12-27 2014-06-18 農業生産法人株式会社 熱帯資源植物研究所 非アルコール性脂肪性肝疾患および／または非アルコール性脂肪肝炎の治療薬
CN104321055A (zh) 2012-01-06 2015-01-28 翁特拉制药公司 游离酸形式的ω-3多不饱和脂肪酸的富含dpa组合物
CN102690856A (zh) * 2012-05-30 2012-09-26 绵阳劲柏生物科技有限责任公司 微生物溶液制作游离型胆汁酸的工艺
US20150299776A1 (en) * 2012-10-03 2015-10-22 Metabogen Ab Identification of a Person having Risk for Atherosclerosis and Associated Disease by the Person's Gut Microbiome and the Prevention of such Diseases
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
DK3628161T3 (da) 2012-11-23 2023-05-30 Seres Therapeutics Inc Synergistiske bakterielle sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
AU2014212004B2 (en) 2013-02-04 2018-09-20 Société des Produits Nestlé S.A. Compositions for treating or preventing or reducing the severity of clostridium difficile related diseases
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
EP2967077A4 (en) 2013-03-15 2016-09-14 Seres Therapeutics Inc NETWORK-BASED MICROBIAL COMPOSITIONS AND METHOD
CN105431173B (zh) 2013-06-11 2020-12-22 好侍健康食品株式会社 向吞噬细胞运输物质的载体
EP3008091A1 (en) * 2013-06-13 2016-04-20 Fast Forward Pharmaceuticals B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
AU2014286177B2 (en) * 2013-07-02 2018-01-18 Austrianova Singapore Pte Ltd. A method of freeze-drying encapsulated cells, freeze-dried encapsulated cells, compositions containing freeze-dried encapsulated cells and uses of such cells and compositions
GB201319531D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
GB201319538D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201319540D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
WO2016071692A1 (en) 2014-11-05 2016-05-12 Optibiotix Limited Prebiotic composition and its method of production
GB201319539D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
KR102611070B1 (ko) 2013-11-25 2023-12-07 세레스 테라퓨틱스, 인코포레이티드 상승적 박테리아 조성물 및 그것의 생산 방법 및 용도
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US10624934B2 (en) * 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
GB2524474B (en) * 2014-03-07 2018-01-31 Genmont Biotech Inc Composition and use of lactobacillus reuteri GMNL-89 in treating type 2 diabetes
US9757404B2 (en) * 2014-09-25 2017-09-12 Astrazeneca Ab Combination comprising an omega-3 fatty acid composition and an SGLT2 inhibitor
MA41611A (fr) 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
CN105132327B (zh) 2015-09-09 2018-12-11 华南理工大学 一种多环芳烃污染修复微囊材料及其制备方法和应用
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
US20190029311A1 (en) * 2015-12-17 2019-01-31 Cj Cheiljedang Corporation Coating method of lactic acid bacteria with increased intestinal survival rate
FR3045383B1 (fr) * 2015-12-18 2019-06-14 Maat Pharma Procede de lyophilisation d'un echantillon de microbiote fecal
CN106361739A (zh) * 2016-08-29 2017-02-01 大连槿藏商贸有限公司 共轭亚油酸或其衍生物在制备乙醛脱氢酶促进剂方面的应用
EP4660295A3 (en) * 2016-10-28 2026-03-11 Vedanta Biosciences, Inc. Methods and compositions for preserving bacteria
KR20180049731A (ko) * 2016-11-03 2018-05-11 주식회사 쎌바이오텍 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물
KR101938865B1 (ko) * 2016-11-03 2019-01-16 주식회사 쎌바이오텍 골 질환, 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물
US10590496B2 (en) * 2016-11-29 2020-03-17 Wedea Inc. Composition for preventing and treating degenerative brain disease using novel lactic acid bacteria
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
RU2019128585A (ru) * 2017-02-16 2021-03-16 Адзиномото Ко., Инк. Полимерная сфера
KR101999693B1 (ko) * 2017-06-13 2019-07-15 부산대학교 산학협력단 산성 환경에서 프로바이오틱스를 보호하는 프로바이오틱스 전달용 하이드로겔 제제 및 이를 포함하는 프로바이오틱스 전달용 조성물
CN107365705B (zh) * 2017-07-14 2021-01-12 江苏微康生物科技有限公司 一种油溶性益生菌冻干菌粉的冻干保护剂及其应用
MX2020001774A (es) 2017-08-14 2020-09-09 Seres Therapeutics Inc Composiciones y métodos para tratar enfermedad colestásica.
SG11201911984QA (en) * 2017-09-29 2020-01-30 Univ Industry Cooperation Group Kyung Hee Univ Novel lactic acid bacteria and use thereof
BR112020008552A2 (pt) 2017-10-30 2020-12-29 Seres Therapeutics, Inc. métodos e composições para tratamento de resistência a antibiótico
WO2019092608A1 (en) * 2017-11-08 2019-05-16 Materias S.R.L. In situ gelifying powder
CN108102985B (zh) * 2018-02-12 2020-08-04 江南大学 一种复配天然酵母发酵制备面包的方法
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN108841898A (zh) * 2018-07-16 2018-11-20 安徽民祯生物工程有限公司 一种透性化酵母细胞生产海藻糖的方法
CN112423842A (zh) * 2018-07-16 2021-02-26 威斯康星州医药大学股份有限公司 罗伊特环素或罗特氏乳杆菌用于减少增重
WO2020055547A2 (en) 2018-08-18 2020-03-19 Seed Health, Inc. Methods and compositions for honey bee health
US12414971B2 (en) 2018-09-25 2025-09-16 Duke University Methods and compositions to treat and prevent infection
CN109266766B (zh) * 2018-10-10 2021-10-19 中国人民解放军第三0二医院 肠道微生物作为胆管细胞癌诊断标志物的用途
EP3870154A4 (en) 2018-10-22 2022-07-27 Research Institute at Nationwide Children's Hospital COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ANTIBIOTIC-INDUCED PATHOLOGIES USING PROBIOTICS IN BIOFILM STATE
KR102447791B1 (ko) * 2018-10-30 2022-10-04 씨제이웰케어 주식회사 유산균의 동결 보호를 위한 시스테인 또는 이의 염의 용도
AU2019394973B2 (en) * 2018-12-07 2025-07-31 Pivot Bio, Inc. Polymer compositions with improved stability for nitrogen fixing microbial products
CN110108815B (zh) * 2019-05-24 2022-01-04 江西省科学院生物资源研究所 一种用于二十八烷醇预防肝损伤效果的体外评价方法
CN112007051B (zh) * 2019-05-28 2022-05-10 景岳生物科技股份有限公司 一种预防中风及改善中风严重度的组合物及其用途
WO2020247536A1 (en) 2019-06-03 2020-12-10 Research Institute At Nationwide Children's Hospital Prebiotic formulations for prevention of sepsis and necroenterocolitis induced neurodevelopmental deficiencies
WO2021048172A2 (en) 2019-09-09 2021-03-18 River Stone Biotech Aps Delivery vehicle for in situ delivering of pharmaceutical agents
TWI719691B (zh) * 2019-10-28 2021-02-21 葡萄王生技股份有限公司 羅伊氏乳桿菌（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｅｕｔｅｒｉ）菌株ＧＫＲ１用於製備降低尿酸之組成物的用途
KR102274678B1 (ko) * 2020-07-16 2021-07-12 (주)코엔바이오 신규한 락토바실러스 플란타룸 아종 플란타룸 Ｃｅｂ－ｋｃ－００７ 균주 및 이를 포함하는 항비만 효능을 가지는 조성물
CN112168847A (zh) * 2020-09-30 2021-01-05 浙江大学 罗伊氏乳杆菌在制备治疗急性肝衰竭药物中的用途
CN112618665B (zh) * 2020-12-19 2022-06-14 杭州益品新五丰药业有限公司 一种提高免疫反应的糠甾醇-谷维素联合用药制剂
CN112603912A (zh) * 2020-12-23 2021-04-06 广东省农业科学院动物科学研究所 罗伊氏菌素在畜禽养殖方面的应用
KR102215599B1 (ko) * 2020-12-28 2021-02-15 주식회사 에이치이엠 신규한 비피도박테리움 애니멀리스 락티스 hem20-01 균주, 및 상기 균주 또는 이의 배양물을 포함하는 우울증 치료용 조성물
CN113604402B (zh) * 2021-08-30 2023-07-21 江苏恒顺醋业股份有限公司 一种特异性的乳酸菌培养基及其培养方法和应用
EP4166002A1 (en) * 2021-10-12 2023-04-19 Evonik Operations GmbH Microbial preparations containing specific cryoprotectants
CN114107066A (zh) * 2021-11-19 2022-03-01 广东容大生物股份有限公司 高活性高稳定性益生菌规模化制备技术开发与示范
CN114010665A (zh) * 2021-11-30 2022-02-08 西南医科大学附属医院 罗伊氏乳杆菌在制备预防和/或治疗酒精性肝病的药物中的应用
CN115607576A (zh) * 2022-09-29 2023-01-17 青岛东海药业有限公司 一种用于防治糖尿病及白色念珠菌感染并发症的组合物及其应用
CN115494244B (zh) * 2022-11-21 2023-03-24 保定佳瑞源生物芯片有限公司 一种癌抗原ca724的吖啶酯抗体标记稀释液及其应用
CN116870155A (zh) * 2023-05-22 2023-10-13 遵义医科大学附属医院 一种离子通道阻滞剂在治疗和/或预防肝纤维化中的应用
CN117187145B (zh) * 2023-10-20 2024-07-16 深圳保时健生物工程有限公司 一株具有降脂、降血糖和减重功能的嗜酸乳杆菌goldgut-la100及其应用
CN118497081B (zh) * 2024-07-09 2024-10-11 云南大学 一种发酵粘液乳杆菌iobra9848及其分离方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362711A (en) * 1980-07-11 1982-12-07 Evreka Inc. Blood cholesterol level reducing agent and method
NL9101537A (nl) 1991-09-11 1993-04-01 Tno Lactobacilli met genetisch gemodificeerde galzouthydrolytische activiteit, produktie en toepassing daarvan.
US5716615A (en) * 1992-02-10 1998-02-10 Renata Maria Anna Cavaliere Vesely Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use
US5686276A (en) * 1995-05-12 1997-11-11 E. I. Du Pont De Nemours And Company Bioconversion of a fermentable carbon source to 1,3-propanediol by a single microorganism
US5534253A (en) * 1995-06-07 1996-07-09 Biogaia Ab Method of treating enteropathogenic bacterial infections in poultry
GB9601333D0 (en) * 1996-01-23 1996-03-27 Univ Mcgill Microencapsulated genetically engineered microorganisms for clinical application
KR100387245B1 (ko) * 1997-10-17 2003-08-19 일양약품주식회사 유산균의안정화를위한미세장용성코팅과립
US6811786B1 (en) * 1999-04-01 2004-11-02 Ganeden Biotech, Inc. Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions
DE19956400B4 (de) 1999-11-24 2005-09-08 Sagredos, Angelos, Prof. Dr. Therapeutisch wirksame Zusammensetzung, ein Verfahren zu ihrer Herstellung und ihre Verwendung
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
EP1264893A1 (en) 2001-06-08 2002-12-11 Teagasc Dairy Products Research Centre CLA biosynthesis by bifidobacteria
EP1494651A4 (en) * 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
US7939061B2 (en) 2003-02-28 2011-05-10 Micropharma Limited Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides
AU2005294200A1 (en) * 2004-10-08 2006-04-20 Georgia Tech Research Corporation Microencapsulation of cells in hydrogels using electrostatic potentials
WO2007140613A1 (en) 2006-06-06 2007-12-13 Mcgill University Fermented milk product and use thereof
US20100047320A1 (en) * 2006-09-07 2010-02-25 Satya Prakash Oral polymeric membrane feruloyl esterase producing bacteria formulation
NL1032840C2 (nl) 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis
CN101273757B (zh) * 2008-03-31 2011-02-09 北京市农林科学院 罗伊氏乳酸杆菌冻干制剂及其制备方法
CN102481322A (zh) 2009-05-01 2012-05-30 微制药有限公司 预防和治疗退化性疾病的细菌组合物

Also Published As

Publication number Publication date
JP2012525338A (ja) 2012-10-22
US20110217368A1 (en) 2011-09-08
AU2010242498A1 (en) 2011-12-22
EP3067056A1 (en) 2016-09-14
JP2015127338A (ja) 2015-07-09
JP6100526B2 (ja) 2017-03-22
HRP20160598T1 (hr) 2016-07-29
EP2419114A4 (en) 2013-07-31
RU2571211C2 (ru) 2015-12-20
EP2419114A1 (en) 2012-02-22
DK2419114T3 (en) 2016-07-25
CA2796929A1 (en) 2010-11-04
US10660857B2 (en) 2020-05-26
RU2011148944A (ru) 2013-06-10
PL2419114T3 (pl) 2016-09-30
CN102481322A (zh) 2012-05-30
PL2419114T5 (pl) 2019-09-30
DK2419114T4 (da) 2019-05-27
ES2578081T5 (es) 2019-10-16
CA2796929C (en) 2020-03-10
ES2578081T3 (es) 2016-07-20
EP2419114B1 (en) 2016-04-20
WO2010124387A1 (en) 2010-11-04
EP2419114B2 (en) 2019-02-27
KR20120015335A (ko) 2012-02-21
HRP20160598T4 (hr) 2019-06-28

Similar Documents

Publication Publication Date Title
BRPI1009920A2 (pt) composições bacterianas para profilaxina e tratamento de doença degenerativa.
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BR112012003092A2 (pt) composições e métodos para implantação de tecido adiposo processado e produtos de tecido adiposo processados.
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BR112012004979A2 (pt) composições para o tratamento de semente e métodos
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI0908087A2 (pt) Composições e métodos para implante de tecido adipose e produtos de tecido adiposo
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI1010849A2 (pt) parafuso para ossos.
MX379016B (es) Composiciones y metodos para tratar enfermedad de gaucher.
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BRPI0818732A2 (pt) Composições de análogo de prostaglandina e métodos para tratar condições relacionadas epiteliais.
BRPI0916862A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
BRPI1014759A2 (pt) composto útil para o tratamento de doenças degenerativas e inflamatórias
BRPI0807918A2 (pt) composições e método para preservação de tecido
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
BRPI1006229A2 (pt) composição incluindo uma quantidade suficiente de curcumina
BRPI0911612A2 (pt) composições e métodos para o tratamento da esclerose múltipla.
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI1006821A2 (pt) composições para o tratamento da doença de refluxo gastro-esofágico (gerd).
BRPI0914410A2 (pt) composição de polidesoxirribonucleotídeo injetável para o tratamento de doenças osteoarticulares.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: UAS LABORATORIES, LLC. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: CHR. HANSEN A/S (DK)

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL